Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：35

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[21] Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study [J].

Kappos, Ludwig ;

Gold, Ralf ;

Miller, David H. ;

MacManus, David G. ;

Havrdova, Eva ;

Limmroth, Volker ;

Polman, Chris H. ;

Schmierer, Klaus ;

Yousry, Tarek A. ;

Eraksoy, Mefkure ;

Meluzinova, Eva ;

Dufek, Michal ;

Yang, Minhua ;

Dawson, Kate ;

O'Neill, Gilmore N. .

MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (03) :314-321

[22] Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis [J].

Putzki, N. ;

Fischer, J. ;

Gottwald, K. ;

Reifschneider, G. ;

Ries, S. ;

Siever, A. ;

Hoffmann, F. ;

Kaefferlein, W. ;

Kausch, U. ;

Liedtke, M. ;

Kirchmeier, J. ;

Gmuend, S. ;

Richter, A. ;

Schicklmaier, P. ;

Niemczyk, G. ;

Wernsdoerfer, C. ;

Hartung, H. P. .

EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (06) :713-720

[23] Tremor in Patients with Relapsing-Remitting Multiple Sclerosis: Clinical Characteristics and Impact on Quality of Life [J].

Shalash, Ali ;

Elhodeby, Ahmed Mohamed ;

Saad, Mahmoud ;

Ibrahim, Yosra Abdelzaher ;

Hamid, Eman ;

Nasef, Ayman .

MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (07) :1099-1106

[24] Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis [J].

Tsantes, E. ;

Curti, E. ;

Ferraro, D. ;

Lugaresi, A. ;

Baldi, E. ;

Montepietra, S. ;

Immovilli, P. ;

Simone, A. M. ;

Mancinelli, L. ;

Strumia, S. ;

Vitetta, F. ;

Foschi, M. ;

Ferri, C. ;

Ferrarini, C. ;

Sola, P. ;

Granella, F. .

EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (01) :269-277

[25] Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study [J].

Comi, Giancarlo ;

Leocani, Letizia ;

Ferini-Strambi, Luigi ;

Radaelli, Marta ;

Costa, Gloria D. ;

Lanzillo, Roberta ;

Lus, Giacomo ;

Bianchi, Valentina ;

Traccis, Sebastiano ;

Capone, Fioravante ;

Grimaldi, Luigi M. E. ;

Salemi, Giuseppe ;

Cardillo, Alessandra ;

Zipoli, Valentina .

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (01)

[26] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study [J].

Irene Eriksson ;

Thomas Cars ;

Fredrik Piehl ;

Rickard E. Malmström ;

Björn Wettermark ;

Mia von Euler .

European Journal of Clinical Pharmacology, 2018, 74 :219-226

[27] The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary [J].

Fricska-Nagy, Zsanett ;

Fuvesi, Judit ;

Rozsa, Csilla ;

Komoly, Samuel ;

Jakab, Gabor ;

Csepany, Tunde ;

Jobbagy, Zita ;

Lencses, Gyula ;

Vecsei, Laszlo ;

Bencsik, Krisztina .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 :26-32

[28] Oral health-related quality of life is more strongly correlated with mental health than with oral health in relapsing-remitting multiple sclerosis [J].

Nangle, Matthew R. ;

Manchery, Nithin ;

Swayne, Andrew ;

Boocock, Helen ;

Blum, Stefan ;

Henry, Julie D. .

JOURNAL OF ORAL REHABILITATION, 2023, 50 (01) :62-68

[29] Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews [J].

Gudesblatt, Mark ;

Roman, Cortnee ;

Singer, Barry A. ;

Schmidt, Hollie ;

Thomas, Jessica ;

Shankar, Sai L. ;

Lyons, Jennifer ;

Kapadia, Shivani .

ADVANCES IN THERAPY, 2022, 39 (07) :3199-3213

[30] Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews [J].

Mark Gudesblatt ;

Cortnee Roman ;

Barry A. Singer ;

Hollie Schmidt ;

Jessica Thomas ;

Sai L. Shankar ;

Jennifer Lyons ;

Shivani Kapadia .

Advances in Therapy, 2022, 39 :3199-3213

← 1 2 3 4 5 →